Faculty of Medicine, University of New South Wales, Sydney, Australia.
Centre for Healthy Brain Aging, Discipline of Psychiatry & Mental Health, School of Clinical Medicine, University of New South Wales, Sydney, Australia.
JAMA Netw Open. 2023 Sep 5;6(9):e2333353. doi: 10.1001/jamanetworkopen.2023.33353.
The utility of antihypertensives and ideal blood pressure (BP) for dementia prevention in late life remains unclear and highly contested.
To assess the associations of hypertension history, antihypertensive use, and baseline measured BP in late life (age >60 years) with dementia and the moderating factors of age, sex, and racial group.
Longitudinal, population-based studies of aging participating in the Cohort Studies of Memory in an International Consortium (COSMIC) group were included. Participants were individuals without dementia at baseline aged 60 to 110 years and were based in 15 different countries (US, Brazil, Australia, China, Korea, Singapore, Central African Republic, Republic of Congo, Nigeria, Germany, Spain, Italy, France, Sweden, and Greece).
Participants were grouped in 3 categories based on previous diagnosis of hypertension and baseline antihypertensive use: healthy controls, treated hypertension, and untreated hypertension. Baseline systolic BP (SBP) and diastolic BP (DBP) were treated as continuous variables. Reporting followed the Preferred Reporting Items for Systematic Review and Meta-Analyses of Individual Participant Data reporting guidelines.
The key outcome was all-cause dementia. Mixed-effects Cox proportional hazards models were used to assess the associations between the exposures and the key outcome variable. The association between dementia and baseline BP was modeled using nonlinear natural splines. The main analysis was a partially adjusted Cox proportional hazards model controlling for age, age squared, sex, education, racial group, and a random effect for study. Sensitivity analyses included a fully adjusted analysis, a restricted analysis of those individuals with more than 5 years of follow-up data, and models examining the moderating factors of age, sex, and racial group.
The analysis included 17 studies with 34 519 community dwelling older adults (20 160 [58.4%] female) with a mean (SD) age of 72.5 (7.5) years and a mean (SD) follow-up of 4.3 (4.3) years. In the main, partially adjusted analysis including 14 studies, individuals with untreated hypertension had a 42% increased risk of dementia compared with healthy controls (hazard ratio [HR], 1.42; 95% CI 1.15-1.76; P = .001) and 26% increased risk compared with individuals with treated hypertension (HR, 1.26; 95% CI, 1.03-1.53; P = .02). Individuals with treated hypertension had no significant increased dementia risk compared with healthy controls (HR, 1.13; 95% CI, 0.99-1.28; P = .07). The association of antihypertensive use or hypertension status with dementia did not vary with baseline BP. There was no significant association of baseline SBP or DBP with dementia risk in any of the analyses. There were no significant interactions with age, sex, or racial group for any of the analyses.
This individual patient data meta-analysis of longitudinal cohort studies found that antihypertensive use was associated with decreased dementia risk compared with individuals with untreated hypertension through all ages in late life. Individuals with treated hypertension had no increased risk of dementia compared with healthy controls.
抗高血压药物的效用和晚年理想血压(BP)对预防痴呆仍不清楚,且极具争议。
评估高血压病史、降压药物使用以及晚年(年龄>60 岁)测量的血压与痴呆的相关性,并评估年龄、性别和种族群体的调节因素。
纳入了参与国际认知老化联盟记忆队列研究(COSMIC)组的纵向、基于人群的老龄化研究。参与者为基线时无痴呆、年龄在 60 至 110 岁之间的个体,来自 15 个不同国家(美国、巴西、澳大利亚、中国、韩国、新加坡、中非共和国、刚果共和国、尼日利亚、德国、西班牙、意大利、法国、瑞典和希腊)。
根据先前的高血压诊断和基线降压药物使用情况,将参与者分为 3 组:健康对照组、治疗性高血压组和未治疗性高血压组。基线收缩压(SBP)和舒张压(DBP)被视为连续变量。报告遵循个体参与者数据系统评价和荟萃分析的首选报告项目指南。
主要结局是全因痴呆。采用混合效应 Cox 比例风险模型评估暴露与关键结局变量之间的相关性。使用非线性自然样条模型来评估基线 BP 与痴呆之间的关系。主要分析是部分调整 Cox 比例风险模型,控制年龄、年龄平方、性别、教育程度、种族群体和研究的随机效应。敏感性分析包括完全调整分析、对随访数据超过 5 年的个体的限制分析,以及检查年龄、性别和种族群体调节因素的模型。
分析包括 17 项研究,涉及 34519 名居住在社区的老年成年人(20160 名[58.4%]为女性),平均(SD)年龄为 72.5(7.5)岁,平均(SD)随访时间为 4.3(4.3)年。在主要的部分调整分析中,包括 14 项研究,与健康对照组相比,未治疗性高血压组痴呆风险增加 42%(风险比[HR],1.42;95%CI,1.15-1.76;P=0.001),与治疗性高血压组相比,痴呆风险增加 26%(HR,1.26;95%CI,1.03-1.53;P=0.02)。与健康对照组相比,治疗性高血压组的痴呆风险无显著增加(HR,1.13;95%CI,0.99-1.28;P=0.07)。降压药物使用或高血压状态与痴呆的相关性与基线 BP 无关。在任何分析中,基线 SBP 或 DBP 均与痴呆风险无显著相关性。在任何分析中,年龄、性别或种族群体均无显著交互作用。
这项对纵向队列研究的个体患者数据荟萃分析发现,与未经治疗的高血压患者相比,降压药物的使用与整个晚年的痴呆风险降低有关。与健康对照组相比,接受治疗的高血压患者痴呆风险无增加。